



5.90.060

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	September 30, 2022
<b>Subject:</b>	Spevigo	<b>Page:</b>	1 of 6

---

**Last Review Date:** September 6, 2024

---

## Spevigo

### Description

#### Spevigo (spesolimab-sbzo)

---

#### Background

Spevigo (spesolimab-sbzo) is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. This prevents the subsequent activation of the IL36R and downstream activation of pro-inflammatory and pro-fibrotic pathways (1).

#### Regulatory Status

FDA-approved indication: Spevigo is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg (1).

Spevigo may increase the risk of infections. Treatment with Spevigo is not recommended for use in patients with any clinically important active infection until the infection resolves or is adequately treated (1).

Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with Spevigo. Spevigo should not be administered to patients with active TB infection. Anti-TB therapy should be considered prior to initiating Spevigo in patients with latent TB or a history of TB in whom an adequate course of treatment cannot be confirmed (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	September 30, 2022
<b>Subject:</b>	Spevigo	<b>Page:</b>	2 of 6

---

Spevigo-associated hypersensitivity reactions may include immediate reactions such as anaphylaxis and delayed reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) (1).

The use of live vaccines with Spevigo should be avoided (1).

The safety and effectiveness of Spevigo in pediatric patients less than 12 years of age and weighing less than 40kg have not been established (1).

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Spevigo may be considered **medically necessary** if the conditions indicated below are met.

Spevigo may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 12 years of age or older

### Diagnosis

Patient must have the following:

1. Generalized pustular psoriasis (GPP)
  - a. GPP flares are of moderate-to-severe intensity (e.g., at least 5% of body surface area covered with erythema and the presence of pustules)

**AND ALL** of the following:

1. Patient has had an inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
  - a. Methotrexate
  - b. Cyclosporine

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	September 30, 2022
<b>Subject:</b>	Spevigo	<b>Page:</b>	3 of 6

---

- c. Oral retinoid
2. Patient weight  $\geq$  40kg
3. Prescriber agrees to monitor for hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS)
4. Result for latent TB infection is negative **OR** result was positive for latent TB and patient completed treatment (or is receiving treatment) for latent TB
5. Absence of active infection (including tuberculosis)
6. **NOT** used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
7. **NOT** given concurrently with live vaccines

---

## Prior – Approval *Renewal* Requirements

**Age** 12 years of age or older

### Diagnosis

Patient must have the following:

1. Generalized pustular psoriasis (GPP)
  - a. Improvement or stabilization of patient's condition (e.g., reduction in the frequency or severity of flares)

**AND ALL** of the following:

1. Patient weight  $\geq$  40kg
2. Prescriber agrees to monitor for hypersensitivity reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS)
3. Absence of active infection (including tuberculosis)
4. **NOT** used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 1)
5. **NOT** given concurrently with live vaccines

### Policy Guidelines

#### Pre - PA Allowance

None

#### Prior - Approval Limits

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	September 30, 2022
<b>Subject:</b>	Spevigo	<b>Page:</b>	4 of 6

**Quantity** 4 IV vials + 26 SC syringes

**Duration** 12 months

### **Prior – Approval *Renewal* Limits**

Same as above

### Rationale

#### **Summary**

Spevigo is an interleukin-36 receptor antagonist that is indicated for the treatment of generalized pustular psoriasis (GPP) and for prevention of flares. Spevigo may cause hypersensitivity reactions including DRESS. Spevigo should not be given to patients with clinically important active infections, including TB. The safety and effectiveness of Spevigo in pediatric patients less than 12 years of age and weighing less than 40kg have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Spevigo while maintaining optimal therapeutic outcomes.

#### **References**

1. Spevigo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2024.
2. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445-86.

### Policy History

Date	Action
September 2022	Addition to PA
December 2022	Annual review
September 2023	Annual review
March 2024	Annual review
April 2024	Per PI update, lowered age requirement to 12 years and older weighing 40 kg or more. Added subcutaneous dosage form. Changed indication to just GPP. Added renewal requirements
June 2024	Annual review
September 2024	Annual review

### Keywords

# 5.90.060

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	October 1, 2024
<b>Subsection:</b>	Topical Products	<b>Original Policy Date:</b>	September 30, 2022
<b>Subject:</b>	Spevigo	<b>Page:</b>	5 of 6

---

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 6, 2024 and is effective on October 1, 2024.**

**Section:** Prescription Drugs**Effective Date:** October 1, 2024**Subsection:** Topical Products**Original Policy Date:** September 30, 2022**Subject:** Spevigo**Page:** 6 of 6**Appendix 1 - List of DMARDs****Biological disease-modifying antirheumatic drugs (DMARDs)**

<b>Generic Name</b>	<b>Brand Name</b>
abatacept	Orencia
adalimumab	Humira
anakinra	Kineret
brodalumab	Siliq
certolizumab	Cimzia
etanercept	Enbrel
golimumab	Simponi/Simponi Aria
guselkumab	Tremfya
infliximab	Remicade/Avsola/Inflectra/Renflexis
ixekizumab	Taltz
risankizumab-rzaa	Skyrizi
rituximab	Rituxan/Riabni/Ruxience/Truxima
sarilumab	Kevzara
secukinumab	Cosentyx
spesolimab-sbzo	Spevigo
tildrakizumab-asmn	Ilumya
tocilizumab	Actemra
ustekinumab	Stelara
vedolizumab	Entyvio

**Targeted synthetic disease-modifying antirheumatic drugs (DMARDs)**

<b>Generic Name</b>	<b>Brand Name</b>
apremilast	Otezla
baricitinib	Olumiant
deucravacitinib	Sotyktu
tofacitinib	Xeljanz/XR
upadactinib	Rinvoq